Dosing & Uses
Dosage Forms & Strengths
injectable solution
- 150 IU/mL (2mL and 10mL vials) (HyperRAB S/D, Imogam Rabies HT, KenRab)
- 300 IU/mL (1mL, 3mL, and 5mL vials) (HyperRAB)
Rabies, Postexposure Prophylaxis
Indicated for passive, transient postexposure prophylaxis of rabies infection, when administered immediately after contact with a rabid or possibly rabid animal
20 International Units/kg, infiltrate locally around bite
Inject any remaining volume IM into the upper arm deltoid region or, in small children, into the anterolateral aspect of the thigh
If bite site is unknown or indeterminate, or difficult to administer (eg, lips, fingers, knees); administer RIG at site(s) distant from the site of the rabies vaccine
Dosage Forms & Strengths
injectable solution
- 150 IU/mL (2mL and 10mL vials) (HyperRAB S/D, Imogam Rabies HT, KenRab)
- 300 IU/mL (1mL, 3mL, and 5mL vials) (HyperRAB)
Rabies, Postexposure Prophylaxis
Indicated for passive, transient postexposure prophylaxis of rabies infection, when administered immediately after contact with a rabid or possibly rabid animal
20 International Units/kg, infiltrate locally around bite
Inject any remaining volume IM into the upper arm deltoid region or, in small children, into the anterolateral aspect of the thigh
If bite site is unknown or indeterminate, or difficult to administer (eg, lips, fingers, knees); administer RIG at site(s) distant from the site of the rabies vaccine
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (6)
- axicabtagene ciloleucel
rabies immune globulin, human (RIG), axicabtagene ciloleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.
- brexucabtagene autoleucel
rabies immune globulin, human (RIG), brexucabtagene autoleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.
- ciltacabtagene autoleucel
rabies immune globulin, human (RIG), ciltacabtagene autoleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.
- idecabtagene vicleucel
rabies immune globulin, human (RIG), idecabtagene vicleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.
- lisocabtagene maraleucel
rabies immune globulin, human (RIG), lisocabtagene maraleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.
- tisagenlecleucel
rabies immune globulin, human (RIG), tisagenlecleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.
Monitor Closely (10)
- BCG vaccine live
rabies immune globulin, human (RIG) decreases effects of BCG vaccine live by Other (see comment). Use Caution/Monitor. Comment: High dose rabies immunoglobulin may impair response to active immunization.
- efgartigimod alfa
efgartigimod alfa will decrease the level or effect of rabies immune globulin, human (RIG) by receptor binding competition. Use Caution/Monitor. Coadministration of efgartigimod with medications that bind to the human neonatal Fc receptor may lower systemic exposures and effectiveness of such medications. Closely monitor for reduced effectiveness of medications that bind to the human neonatal Fc receptor. If long-term use of such medications is essential, consider discontinuing efgartigimod and using alternative therapies.
- measles (rubeola) vaccine
rabies immune globulin, human (RIG) decreases effects of measles (rubeola) vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months.
- measles mumps and rubella vaccine, live
rabies immune globulin, human (RIG) decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months.
- measles, mumps, rubella and varicella vaccine, live
rabies immune globulin, human (RIG) decreases effects of measles, mumps, rubella and varicella vaccine, live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months.
- rabies vaccine
rabies immune globulin, human (RIG) decreases effects of rabies vaccine by Other (see comment). Use Caution/Monitor. Comment: RIG may be administered concurrently with and up to 8 days after rabies vaccine. High dose rabies immunoglobulin may impair response to active immunization. .
- rabies vaccine chick embryo cell derived
rabies immune globulin, human (RIG) decreases effects of rabies vaccine chick embryo cell derived by Other (see comment). Use Caution/Monitor. Comment: RIG may be administered concurrently with and up to 8 days after rabies vaccine. High dose rabies immunoglobulin may impair response to active immunization. .
- rubella vaccine
rabies immune globulin, human (RIG) decreases effects of rubella vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months.
- smallpox (vaccinia) vaccine, live
rabies immune globulin, human (RIG) decreases effects of smallpox (vaccinia) vaccine, live by Other (see comment). Use Caution/Monitor. Comment: High dose rabies immunoglobulin may impair response to active immunization.
- varicella virus vaccine live
rabies immune globulin, human (RIG) decreases effects of varicella virus vaccine live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months.
Minor (1)
- protein a column
protein a column decreases levels of rabies immune globulin, human (RIG) by Other (see comment). Minor/Significance Unknown. Comment: Since Prosorba binds IgG, it could theoretically interfere with the levels and/or effects of pharmacologic immune globulins.
Adverse Effects
>10%
Injection site pain (33%)
Headache (15%)
1-10%
Muscle pain (9%)
Upper respiratory tract infection (9%)
Joint pain (6%)
Dizziness (6%)
Fatigue (6%)
Abdominal pain (4%)
Blood in urine (4%)
Nausea (4%)
Feeling faint (4%)
Bruising (3%)
Sunburn (3%)
WBCs in urine (3%)
Warnings
Contraindications
None
Cautions
Patients who can document previous complete rabies pre-exposure prophylaxis or complete postexposure prophylaxis should only receive a booster rabies vaccine without RIG, owing to RIG interference with anamnestic response to the vaccine
Hemolysis may occur, particularly in individuals at high risk (eg, thrombocytopenia, bleeding disorders)
Monitor patients at increased risk of thrombosis or thrombotic complications for at least 24 hr
Caution with prior allergic reactions to immune globulins (RIG contains small quantity of IgA)
Avoid immunization with measles vaccine within 4 months after RIG; avoid other live attenuated vaccines for 3 months
Do NOT give IV; do not inject into a blood vessel because of the risk of severe allergic or hypersensitivity reaction, including decreased blood pressure and anaphylactic shock
A transient rise of the various passively transferred antibodies in the patient’s blood may result in misleading positive results of serologic tests; passive transmission of antibodies to erythrocyte antigens (eg, A, B, and D), may interfere with serologic tests for red cell antibodies such as the antiglobulin test (Coombs test)
RIG is derived from human plasma; therefore, the potential exists for viral transmission (eg, CJD)
Pregnancy & Lactation
Pregnancy
Has not been studied in pregnant women
Animal and reproductive studies have not been conducted
Lactation
Unknown if excreted in human milk
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Human immune globulins from donors
Pharmcokinetics
Half-life: 17.9 days
Peak plasma time: 7 days (range: 3-14 days)
Administration
Injection
Infiltrate locally around bite; inject any remaining volume IM into the upper arm deltoid region or, in small children, into the anterolateral aspect of the thigh
If IM administration is contraindicated (eg, in patients with uncorrectable bleeding disorders), administer RIG by SC injection (there are no clinical efficacy data to support SC route)
Always administer in conjunction with rabies vaccine (HDCV); however, do not administer into the same anatomical sites as rabies vaccine
Preferably give concomitantly with vaccine but may be given through 7th day after first dose of vaccine
Do not give repeated doses of RIG once rabies vaccine treatment has started, since this may interfere with the immune response to the rabies vaccine
Do not administer RIG to patients with a history of a complete pre-exposure or postexposure vaccination regimen and confirmed adequate rabies antibody titer
Do not mix with the rabies vaccine or administer in the same syringe with the rabies vaccine
Storage
KedRab
- Refrigerate at 2-8ºC (36-46ºF); do not freeze
- May store at room temperature not exceeding 25ºC (77ºF) for up to 1 month; do not return to refrigeration
HyperRAB
- Refrigerate at 2-8ºC (36-46ºF); do not freeze
- May store at room temperature not exceeding 25ºC (77ºF) for up to 6 months; do not return to refrigeration
Imogam Rabies HT, HyperRAB S/D
- Refrigerate at 2-8ºC (36-46ºF); do not freeze
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| Imogam Rabies-HT (PF) intramuscular - | 150 unit/mL vial |  | |
| HyperRAB S/D (PF) intramuscular - | 150 unit/mL vial |  | |
| HyperRAB S/D (PF) intramuscular - | 150 unit/mL vial |  | |
| Kedrab (PF) intramuscular - | 150 unit/mL vial |  | |
| Kedrab (PF) intramuscular - | 150 unit/mL vial |  |
Copyright © 2010 First DataBank, Inc.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
